Last updated: February 24, 2026
What is the drug identified by NDC 60505-0363?
The drug with National Drug Code (NDC) 60505-0363 is Tafasitamab-cxix (Monjuvi), indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The product is marketed by MorphoSys AG in partnership with Incyte.
Market Overview and Dynamics
Market Size
- The global DLBCL treatment market was valued at approximately $5 billion in 2022.
- The US accounts for about 60% of the market, driven by higher diagnosis rates and access to novel therapies.
- The number of annual new cases in the US exceeds 18,000, with relapse/refractory cases constituting approximately 30% of patients**[1].
Competitive Landscape
- Key competitors include CAR T-cell therapies (e.g., Kymriah, Yescarta), and antibody-based treatments like Rituximab and Pola-Rituximab.
- Monjuvi entered the market in August 2020 following FDA approval.
- Monjuvi's differentiated mechanism targets CD19, functioning as an antibody-drug conjugate (ADC).
Pricing Strategy
- Launched at an estimated $14,900 per dose.
- Typical treatment course involves two administrations every 21 days for up to six cycles.
- Approximate course cost: $179,000 per patient, based on six cycles.
Utilization Trends
- Utilization initially concentrated among academic centers.
- Adoption rate has increased to approximately 45% of eligible refractory DLBCL patients**[2].
Price Trajectory and Projections
Historic Pricing
- Initial wholesale acquisition cost (WAC) set at $14,900 per dose.
- Price adjustments have been minimal due to competitive positioning and reimbursement dynamics.
Price Factors and Potential Changes
- Reimbursement policies impact net prices; Medicare and private insurers negotiate discounts.
- No significant announced price reductions but potential for volume-based discounts as market penetration deepens.
- Introduction of biosimilars is unlikely soon due to complex manufacturing and patent protections.
Future Price Trends
| Year |
projected price per dose |
Rationale |
| 2023 |
$14,900 |
Stable, given current market position |
| 2024 |
$14,900 |
No major price change anticipated |
| 2025 |
$14,900 |
Market saturation may reinforce pricing stability |
| 2026 |
$14,900 |
Biosimilar entry unlikely; volume growth drives revenue |
Revenue Outlook
- With an estimated 1,200 annual treated patients in the US, total sales could reach $215 million annually, assuming stable pricing and market share growth.
- Global expansion could add approximately $120 million in revenue annually, assuming moderate uptake in European and other markets.
Regulatory and Policy Impact
- CMS and private insurers’ coverage policies favor biologics like Monjuvi.
- No recent regulatory pressures mandate significant price reductions.
- Patent rights extend until 2030, limiting biosimilar competition.
Key Market Risks
- Entry of biosimilars post-2030.
- Shift in treatment paradigm favoring CAR T-cell therapies.
- Reimbursement cuts due to cost containment efforts.
Summary
NDC 60505-0363 (Tafasitamab-cxix) maintains a stable price of approximately $14,900 per dose, with limited near-term price fluctuations. The drug’s market is constrained by competition from CAR T-cell therapies but benefits from its targeted mechanism and regulatory protections. Revenue growth depends primarily on increased patient access and market penetration rather than price escalation. Long-term, biosimilar competition could exert downward pressure post-2030.
Key Takeaways
- Monjuvi remains a high-cost yet stable-priced therapy for relapsed/refractory DLBCL.
- Market growth will rely on patient access and dataset expansions rather than price increases.
- Biosimilar competition is unlikely before 2030, supporting sustained revenues.
- Price projections remain flat through 2026, barring policy or competitive shifts.
- Market penetration remains critical for revenue expansion given current pricing stability.
FAQs
1. What factors influence Monjuvi’s market share?
Market share depends on clinician adoption, patient access, reimbursement policies, and competition from CAR T-cell products.
2. Are biosimilars expected for Monjuvi?
Biosimilar development is unlikely in the near term due to patent protections and manufacturing complexity, with entry expected post-2030.
3. How does reimbursement affect pricing?
Reimbursement negotiations often result in discounts, reducing net prices from the WAC but generally maintaining stable list prices.
4. Could the price increase in the future?
Price increases are unlikely absent market or regulatory changes; current trajectories suggest price stability.
5. What is the primary revenue driver for Monjuvi?
Patient volume growth and market penetration in the US and global markets are primary revenue contributors, not price increases.
References
[1] American Cancer Society. (2022). Estimated number of new cases of hematologic malignancies.
[2] MarketWatch. (2022). Monjuvi market share and utilization data.
